Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

Welch, Stephen; Spithoff, Karen; Rumble, R. Bryan; Maroun, J.

doi:10.1093/annonc/mdp533

Cited by 166 publications

(123 citation statements)

References 22 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…18 An improvement in survival was found in some studies, and the median survival is 21 months with the addition of biologic agents. [19][20][21] In case of inoperability of liver metastases and in absence of response to systemic chemotherapy, various interventional radiology procedures are considered as an alternative…”

mentioning

confidence: 96%

“…[14][15][16][17] A survival benefit has been shown with the addition of bevacizumab to both first-and second-line therapy, and the reported median survival in several studies ranged between 10.2 and 21.5 months. 18 An improvement in survival was found in some studies, and the median survival is 21 months with the addition of biologic agents. [19][20][21] In case of inoperability of liver metastases and in absence of response to systemic chemotherapy, various interventional radiology procedures are considered as an alternative treatment method in the interdisciplinary therapy management.…”

mentioning

confidence: 96%

See 1 more Smart Citation

Transarterial chemoembolization of unresectable systemic chemotherapy‐refractory liver metastases from colorectal cancer: Long‐term results over a 10‐year period

Gruber‐Rouh

Naguib

Eichler

et al. 2013

Intl Journal of Cancer

View full text Add to dashboard Cite

The aims of the study were to evaluate therapeutic efficacy and to determine the prognostic factors for treatment success in patients with liver metastases from colorectal cancer (CRC) treated with transarterial chemoembolization (TACE). A total of 564 patients (mean age, 60.3 years) with liver metastases of CRC were repeatedly treated with TACE. In total, 3,384 TACE procedures were performed (mean, six sessions per patient). The local chemotherapy protocol consisted of mitomycin C alone (43.1%), mitomycin C with gemcitabine (27.1%), mitomycin C with irinotecan (15.6%) or mitomycin C with irinotecan and cisplatin (15.6%). Embolization was performed with lipiodol and starch microspheres. Tumor response was evaluated using magnetic resonance imaging or computed tomography. The change in tumor size was calculated and the response was evaluated according to the RECIST-Criteria. Survival rates were calculated according to the Kaplan-Meier method. Prognostic factors for patient's survival were evaluated using log-rank test. Evaluation of local tumor control showed partial response in 16.7%, stable disease in 48.2% and progressive disease in 16.7%. The 1-year survival rate after chemoembolization was 62%, the 2-year survival rate was 28% and the 3-year survival rate was 7%. Median survival from the start of chemoembolization treatment was 14.3 months. The indication (p 5 0.001) and initial tumor response (p 5 0.015) were statistically significant factors for patient's survival. TACE is a minimally invasive therapy option for controlling local metastases and improving survival time in patients with hepatic metastases from CRC. TN stage, extrahepatic metastases, number of lesions, tumor location within the liver and choice of chemotherapy protocol of TACE are none significant factors for patient's survival.The development of liver metastases in patients with colorectal cancer (CRC) substantially affects the prognosis of the patient. At the time of first diagnosis of CRC, 20-50% of all patients already present with synchronous liver metastases. Liver metastases develop in about 60-70% of CRC patients during the course of their disease and are the most common cause of death of patients with CRC. [1][2][3] Resection is the only potentially curative therapy for patients with liver metastases from CRC. 4,5 Only 20% of patients with liver metastases will be candidates for resection. With modern oncosurgical approaches, patients with resected liver metastases can experience up to 50-60% 5-year overall survival and a median survival of 46-64 months.6-8 Systemic chemotherapy may achieve this goal in 10-20% of initially unresectable patients. 9,10 The high rate of inoperable patients and intrahepatic recurrence rates are another relevant problem. Currently, the standard first-line treatment of metastatic CRC is a combination of infusional 5-FU, folinic acid with either irinotecan (FOLFIRI) or oxaliplatin (FOLFOX). The response rate to these schedules is 50%, and 50% of patients will progress within 10 months. In second-line therap...

show abstract

mentioning

confidence: 96%

mentioning

confidence: 96%

Transarterial chemoembolization of unresectable systemic chemotherapy‐refractory liver metastases from colorectal cancer: Long‐term results over a 10‐year period

Gruber‐Rouh

Naguib

Eichler

et al. 2013

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The combination of doublet chemotherapy regimens with biological agents, such as bevacizumab (a humanized monoclonal antibody that inhibits vascular endothelial growth factor (Ferrara et al, 2003) has been shown to prolong PFS, OS and RR although toxicity was also increased (Kabbinavar et al, 2005;Grothey et al, 2008;Hochster et al, 2008;Saltz et al, 2008;Welch et al, 2010;Macedo et al, 2012). Although all of this findings, the optimal combination of first-line treatment is still unclear (Cunningham et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology

Duran

Karaca²,

Besiroglu³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The monoclonal VEGF-A antibody, bevacizumab, has been shown to modestly improve OS in addition to chemotherapy in metastatic CRC in several meta-analyses [105][106][107][108], and is currently established within the standard armamentarium in first line management of this disease. The role for the bevacizumab in EOC is also evolving with two large phase III trials confirming improve PFS in addition to adjuvant chemotherapy following primary debulking surgery [109,110] and in both the recurrent platinum sensitive [111] and resistant settings [112].…”

Section: Targeted Therapeutic Approaches 81 Vegf Inhibitionmentioning

confidence: 99%

Mucinous ovarian cancer: A therapeutic review

Wen

Rush

Rickett

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Highlights Mucinous epithelial ovarian cancer (mEOC) is a rare chemo-resistant subtype of ovarian cancer with distinct epidemiology, pathology and natural history.  mEOC can often masquerade as metastatic mucinous tumours from the gastrointestinal (GI) tract.  Molecularly, in contrast to high-grade serous ovarian cancer (HGSOC), mEOC are far less defined by p53 mutations and instead commonly harbour KRAS and HER 2 mutations.  The current gold standard of 1 st line platinum/taxane doublet chemotherapy, is more tailored towards HGSOC and generally ineffective for mEOC.  This review summarises the limited evidence for using GI style chemotherapeutic agents in treating mEOC and explores novel therapeutic possibilities such as targeting HER2, VEGF and Src. AbstractMucinous ovarian cancer represents approximately 3% of epithelial ovarian cancers (EOC).Despite this seemingly low prevalence, it remains a diagnostic and therapeutic conundrum that has resulted in numerous attempts to adopt novel strategies in managing this disease.Anecdotally, there has been a prevailing notion that established gold standard systemic regimens should be substituted for those utilised in cancers such as gastrointestinal (GI) malignancies; tumours that share more biological similarities than other EOC subtypes. This review summarises the plethora of small studies which have adopted this philosophy and influenced the design of the multinational GOG142 study, which was ultimately terminated due to poor accrual. To date, there is a paucity of evidence to support delivering 'GI style' chemotherapy for mucinous ovarian cancer over and above carboplatin-paclitaxel doublet therapy. Hence there is an urge to develop studies focused on targeted therapeutic agents driven by refined mutational analysis and conducted within the context of harmonised international collaborations.3

show abstract

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

Cited by 166 publications

References 22 publications

Transarterial chemoembolization of unresectable systemic chemotherapy‐refractory liver metastases from colorectal cancer: Long‐term results over a 10‐year period

Transarterial chemoembolization of unresectable systemic chemotherapy‐refractory liver metastases from colorectal cancer: Long‐term results over a 10‐year period

XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology

Mucinous ovarian cancer: A therapeutic review

Contact Info

Product

Resources

About